Faculty of Medicine and Life Sciences, Vaccine Research Center, University of Tampere, Tampere, Finland.
Front Immunol. 2018 Nov 27;9:2782. doi: 10.3389/fimmu.2018.02782. eCollection 2018.
Norovirus (NoV) causes a substantial global burden of acute gastroenteritis in all age groups and the development of NoV vaccine is a high priority. There are still gaps in understanding of protective NoV-specific immunity. Antibody mediated immune responses have been widely studied, but in contrast, the research on NoV-specific human T cell-mediated immunity is very limited. We have recently reported NoV capsid VP1-specific 18-mer peptide (SPSQVTMFPHIIVDVRQL) to induce strong CD8 T cell immune responses in healthy adult donors. This work extends to identify the precise NoV T cell epitope and the restricting human leucocyte antigen (HLA). Pentamer technology was used to detect HLA-A0201-restricted T cell-mediated responses to 10-mer peptide TMFPHIIVDV of four healthy adult blood donors. Immunogenicity of the 10-mer epitope was confirmed by ELISPOT IFN-γ and intracellular cytokine staining (ICS) on flow cytometry. A population of CD3CD8 T lymphocytes binding to HLA-A0201/TMFPHIIVDV pentamers was identified in two HLA-A0201-positive donors. Recognition of the 10-mer epitope by T cells resulted in a strong IFN-γ secretion as shown by ELISPOT assay. In addition, ICS confirmed that high proportion (31 and 59%) of the TMFPHIIVDV epitope-responsive CD3CD8 T cells in the two donors had multifunctional phenotype, simultaneously producing IFN-γ, IL-2 and TNF-α cytokines. In the present study novel human NoV HLA-A0201-restricted minimal 10-mer epitope TMFPHIIVDV in the capsid VP1 was identified. The HLA-peptide pentamer staining of T cells from healthy donor PBMCs and cytokine responses in ELISPOT and ICS assays suggest that this epitope is recognized during NoV infection and activates memory phenotype of the epitope-specific multifunctional CD8 T cells. The importance of this epitope in protection from NoV infection remains to be determined.
诺如病毒(NoV)会导致所有年龄段人群发生大量全球范围内的急性肠胃炎,因此开发 NoV 疫苗成为当务之急。目前,人们对保护性 NoV 特异性免疫仍存在认识上的空白。抗体介导的免疫应答已得到广泛研究,但与之形成鲜明对比的是,针对 NoV 特异性人类 T 细胞介导免疫的研究非常有限。我们最近报道称,NoV 衣壳 VP1 特异性 18 肽(SPSQVTMFPHIIVDVRQL)可诱导健康成年供者产生强烈的 CD8 T 细胞免疫应答。本研究进一步鉴定了精确的 NoV T 细胞表位和限制性人白细胞抗原(HLA)。我们使用五聚体技术检测了来自 4 位健康成年献血者的 10 肽 TMFPHIIVDV 对 HLA-A0201 限制的 T 细胞介导反应。ELISPOT IFN-γ 和流式细胞术的细胞内细胞因子染色(ICS)证实了 10 肽表位的免疫原性。在两位 HLA-A0201 阳性供者中,鉴定到与 HLA-A0201/TMFPHIIVDV 五聚体结合的 CD3CD8 T 淋巴细胞群体。T 细胞对 10 肽表位的识别导致 IFN-γ 的强烈分泌,ELISPOT 检测证实了这一点。此外,ICS 证实,在这两位供者中,有高比例(31%和 59%)的 TMFPHIIVDV 表位反应性 CD3CD8 T 细胞具有多功能表型,同时产生 IFN-γ、IL-2 和 TNF-α 细胞因子。本研究鉴定到 NoV 衣壳 VP1 中 HLA-A0201 限制性最小的 10 肽表位 TMFPHIIVDV。来自健康供者 PBMC 的 HLA-肽五聚体染色以及 ELISPOT 和 ICS 检测中的细胞因子反应表明,在 NoV 感染期间可识别该表位,并激活表位特异性多功能 CD8 T 细胞的记忆表型。该表位在预防 NoV 感染中的重要性仍有待确定。